Sustained clinical benefit of ramucirumab plus erlotinib in EGFR mutated NSCLC, irrespective of the mutation type Sustained clinical benefit of ramucirumab plus erlotinib in EGFR mutated NSCLC, irrespective of the mutation type September 2020 ESMO 2020 Read more
2022 June Covid-19 COVID-19 lessons learned: perspective on future oncology clinical research Read more
2022 May Covid-19 Bivalent beta-containing mRNA-1273.211 booster vaccine generates higher antibody titers than m... Read more
2022 May Covid-19 Anecdotal reports of more extensive staging at cancer diagnosis cannot be confirmed using Antw... Read more
2021 May Covid-19 MYCOBACTERIUM BCG PROTECTS NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS FROM SEVERE COVID-19 PR... Read more